World Wires · story 5203 · unverified · 1 source(s)

uniQure Reports Phase I/II Data for AMT-130 in Huntington's

uniQure announced 48-month data from ongoing Phase I/II studies of ifezuntirgene inilparvovec in Huntington's disease, showing continued slowing of disease

Open in the desk

Coverage

• uniQure Reports Phase I/II Data for AMT-130 in Huntington's GlobeNewswire: public companies · tier D · clear net · 2026-09-29 11:12 UTC

What this site indexes